These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35986867)

  • 41. Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial.
    Joosten LPT; van Doorn S; Hoes AW; Nierman MC; Wiersma NM; Koek HL; Hemels MEW; Huisman MV; Roes KC; van den Bor RM; Buding WF; Rutten FH; Geersing GJ
    BMJ Open; 2019 Dec; 9(12):e032488. PubMed ID: 31888928
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rationale and design of a prospective, multicenter, cross-sectional study of appropriateness evaluation of the prescription of non-vitamin K antagonist oral anticoagulants for Chinese atrial fibrillation patients (Chi-NOACs-AF trial).
    Ding Z; Zhang C; Qian YY; Wang N; Gu ZC; Xu H; Zheng YL
    Ann Transl Med; 2021 Apr; 9(7):580. PubMed ID: 33987278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of non-vitamin K antagonist oral anticoagulants (NOACs) on anticoagulation therapy in rural Australia.
    Bellinge JW; Paul JJ; Walsh LS; Garg L; Watts GF; Schultz C
    Med J Aust; 2018 Jan; 208(1):18-23. PubMed ID: 29320668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of Non-Vitamin K Antagonist Oral Anticoagulants 2008-2016: A Danish Nationwide Cohort Study.
    Haastrup SB; Hellfritzsch M; Rasmussen L; Pottegård A; Grove EL
    Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):452-463. PubMed ID: 29664236
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bleeding risk in patients with atrial fibrillation treated with combined anti-platelet and non-vitamin K antagonist oral anticoagulant therapy.
    Shin DG; Kim S; Kim YR
    Rev Cardiovasc Med; 2022 Jan; 23(1):2. PubMed ID: 35092194
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients.
    Dillinger JG; Aleil B; Cheggour S; Benhamou Y; Béjot Y; Marechaux S; Delluc A; Bertoletti L; Lellouche N
    Arch Cardiovasc Dis; 2018 Feb; 111(2):85-94. PubMed ID: 28988597
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience.
    Simons LA; Ortiz M; Freedman B; Waterhouse BJ; Colquhoun D
    Curr Med Res Opin; 2017 Jul; 33(7):1337-1341. PubMed ID: 28425296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimal Management of Anticoagulation Therapy in Asian Patients With Atrial Fibrillation.
    Cheng WH; Chan YH; Liao JN; Kuo L; Chen SA; Chao TF
    Circ J; 2021 Jul; 85(8):1245-1253. PubMed ID: 34092760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study.
    Huang HK; Liu PP; Hsu JY; Lin SM; Peng CC; Wang JH; Loh CH
    Eur Heart J; 2020 Mar; 41(10):1100-1108. PubMed ID: 32006423
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey.
    Potpara TS; Trendafilova E; Dan GA; Goda A; Kusljugic Z; Manola S; Music L; Gjini V; Pojskic B; Popescu MI; Georgescu CA; Dimitrova ES; Kamenova D; Ekmeciu U; Mrsic D; Nenezic A; Brusich S; Milanov S; Zeljkovic I; Lip GYH;
    Adv Ther; 2017 Aug; 34(8):2043-2057. PubMed ID: 28795332
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis.
    Yang KT; Sun WC; Tsai TJ; Tsay FW; Chen WC; Cheng JS
    Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33375495
    [No Abstract]   [Full Text] [Related]  

  • 53. Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators.
    Carnicelli AP; Hong H; Giugliano RP; Connolly SJ; Eikelboom J; Patel MR; Wallentin L; Morrow DA; Wojdyla D; Hua K; Hohnloser SH; Oldgren J; Ruff CT; Piccini JP; Lopes RD; Alexander JH; Granger CB;
    Am Heart J; 2021 Mar; 233():48-58. PubMed ID: 33296688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction.
    Schwill S; Krug K; Peters-Klimm F; van Lieshout J; Laux G; Szecsenyi J; Wensing M
    BMC Fam Pract; 2018 Jul; 19(1):115. PubMed ID: 30021509
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) Programme.
    Leblanc K; Bell AD; Ezekowitz JA; Tan MK; Laflamme D; Goldin L; Habert J; Lin PJ; Saunders K; Ngui D; Ng AP; Desroches J; Goodman SG;
    Int J Clin Pract; 2020 Dec; 74(12):e13625. PubMed ID: 33448547
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
    Hohnloser SH; Basic E; Nabauer M
    Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.
    Xiong Q; Lau YC; Senoo K; Lane DA; Hong K; Lip GY
    Eur J Heart Fail; 2015 Nov; 17(11):1192-200. PubMed ID: 26335355
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients.
    Song HY; Son KB; Shin JY; Bae S
    Int J Clin Pharm; 2019 Dec; 41(6):1434-1441. PubMed ID: 31522377
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study.
    Jung H; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
    Chest; 2019 Feb; 155(2):354-363. PubMed ID: 30472021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.